Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30991743 | 0.82 | APP (0.51) | APPMAOBDAOMAOALMNA | |
| SCHEMBL25260084 | 0.82 | APP (0.51) | APPMAOBDAOMAOALMNA | |
| SCHEMBL14125786 | 0.80 | SMN1; SMN2 (0.43) | MAOBDAOMAOACYP3A4NPC1 | |
| SCHEMBL25213547 | 0.80 | APP (0.58) | APPMAOBDAOMAOACYP3A4 | |
| SCHEMBL25245698 | 0.79 | MAOB (0.66) | APPMAOBDAOMAOATSHR | |
| SCHEMBL25244489 | 0.78 | DAO (0.51) | APPMAOBDAOMAOACYP1A2 | |
| SCHEMBL10661250 | 0.78 | FFAR1 (0.56) | APPMAOBDAOMAOACYP1A2 | |
| SCHEMBL30991720 | 0.78 | DAO (0.51) | APPMAOBDAOMAOACYP1A2 | |
| SCHEMBL10658131 | 0.77 | DAO (0.50) | APPMAOBDAOMAOACYP1A2 | |
| SCHEMBL11883440 | 0.76 | APP (0.54) | APPMAOBDAOMAOACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025021182-A1 | CYP11A1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-01-30 | — | — | WO | disclosed |
| CN-108137555-B | Indolin-2-one derivatives useful in the treatment of CNS disorders | 豪夫迈·罗氏有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-10377746-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377746-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-3371170-B1 | INDOLIN-2-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISEASES | HOFFMANN LA ROCHE (CH) | 2019-07-31 | — | — | EP | disclosed |
| EP-3371170-B1 | INDOLIN-2-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISEASES | HOFFMANN LA ROCHE (CH) | 2019-07-31 | — | — | EP | disclosed |
| EP-3371170-A1 | INDOLIN-2-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISEASES | H. Hoffnabb-La Roche Ag (CH) | 2018-09-12 | — | — | EP | disclosed |
| US-20180251455-A1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-09-06 | — | — | US | disclosed |
| WO-2017076932-A1 | INDOLIN-2-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017076932-A1 | INDOLIN-2-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-11 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | APP 4630/4885MAOB 2855/4885DAO 2903/4885 |
| US-20180251455-A1 | INDOLIN-2-ONE DERIVATIVES | HTR3C, GRIN2D, DRD2 | APP 553/4885MAOB 219/4885DAO 2973/4885 |
| US-10377746-B2 | Indolin-2-one derivatives | HTR3C, GRIN2D, DRD2 | APP 553/4885MAOB 219/4885DAO 2973/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | APP 4630/4885MAOB 2855/4885DAO 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.